---
title: "SSSW released its semi-annual performance report, with a net profit attributable to the parent company of 3.99 million yuan, a year-on-year decrease of 86.35%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252200960.md"
description: "SSSW released its semi-annual report for 2025, with revenue of 176 million yuan, a year-on-year decrease of 1.05%; net profit attributable to the parent company of 3.99 million yuan, a year-on-year decrease of 86.35%; and a net profit loss of 28.05 million yuan after deducting non-recurring items. The company plans to distribute a cash dividend of 34 yuan for every 10 shares. During the reporting period, the total profit decreased by 78.37%, mainly due to the pressure on product prices caused by centralized procurement in the in vitro diagnostic industry and adjustments in the value-added tax rate"
datetime: "2025-08-08T10:01:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252200960.md)
  - [en](https://longbridge.com/en/news/252200960.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252200960.md)
generator: "portal-rs"
---

# SSSW released its semi-annual performance report, with a net profit attributable to the parent company of 3.99 million yuan, a year-on-year decrease of 86.35%

According to the Zhitong Finance APP, SSSW (688399.SH) disclosed its semi-annual report for 2025, reporting revenue of 176 million yuan, a year-on-year decrease of 1.05%; net profit attributable to shareholders of the listed company was 3.99 million yuan, a year-on-year decrease of 86.35%; the net profit excluding non-recurring items was a loss of 28.05 million yuan, a year-on-year increase; basic earnings per share were 0.05 yuan. The company plans to distribute a cash dividend of 34 yuan (including tax) for every 10 shares to all shareholders.

During the reporting period, the total profit decreased by 78.37% compared to the same period last year, and the net profit attributable to shareholders of the listed company decreased by 86.35% compared to the same period last year. This was mainly due to the pressure on product prices caused by the deep implementation of centralized procurement in the in vitro diagnostic industry nationwide, as well as the adjustment of the value-added tax rate for self-produced testing reagent products to 13% during the reporting period, which led to a decline in gross profit margin, a decrease in the reversal of impairment provisions for receivables, and a reduction in government subsidies

### Related Stocks

- [688399.CN](https://longbridge.com/en/quote/688399.CN.md)

## Related News & Research

- [12:25 ETMarquis Who's Who Honors Kristan Veora Rollins-Miskell](https://longbridge.com/en/news/296381024.md)
- [UNM and ScienceSoft Launch First Statewide WHO Healthy Aging Initiative in US](https://longbridge.com/en/news/296641162.md)
- [LEAD Launch Leaves Accountable Care Technology Buyers Little Time for a Wrong Decision, Q3 Study](https://longbridge.com/en/news/296106866.md)
- [Bucked Up® Launches Hunt: Orange Cream, a Limited-Edition Flavor Built to Fuel Your Hunt](https://longbridge.com/en/news/296524338.md)
- [BUZZ-Faeth Therapeutics rises after FDA grants fast-track status for cancer drug](https://longbridge.com/en/news/296104768.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**